• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

停止复发缓解型和进展型多发性硬化症的疾病修正治疗。

Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis.

机构信息

Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany.

Brain and Mind Centre, University of Sydney, Camperdown.

出版信息

Curr Opin Neurol. 2021 Aug 1;34(4):598-603. doi: 10.1097/WCO.0000000000000960.

DOI:10.1097/WCO.0000000000000960
PMID:33990101
Abstract

PURPOSE OF REVIEW

To assess the reasons for considering discontinuation of disease-modifying therapies (DMTs)in patients with multiple sclerosis (MS). Relevant aspects of the natural history, pathology, and immunology are analyzed.

RECENT FINDINGS

A number of retrospective observational studies in aggregate indicate that stopping DMTs may be attempted in older individuals with stable disease. Prognostic factors have been identified informing about the risk of recurrence of disease activity after DMT discontinuation.

SUMMARY

Several clinical scenarios provide a rationale to stop DMTs in people with MS. Cumulative evidence has been gathered recently allowing us to more precisely weigh the risks against the benefits. This information aids in the decision process.

摘要

目的综述

评估多发性硬化症 (MS) 患者停止疾病修正治疗 (DMT) 的原因。分析了自然史、病理学和免疫学的相关方面。

最近的发现

大量回顾性观察研究表明,对于病情稳定的老年患者,可以尝试停止 DMT。已经确定了预后因素,这些因素可以预测 DMT 停药后疾病活动复发的风险。

总结

多种临床情况为 MS 患者停止 DMT 提供了依据。最近积累了大量证据,使我们能够更精确地权衡风险与收益。这些信息有助于决策过程。

相似文献

1
Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis.停止复发缓解型和进展型多发性硬化症的疾病修正治疗。
Curr Opin Neurol. 2021 Aug 1;34(4):598-603. doi: 10.1097/WCO.0000000000000960.
2
Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.患者对复发缓解型多发性硬化症中改变疾病修饰治疗方案的决策看法。
Mult Scler Relat Disord. 2020 Nov;46:102507. doi: 10.1016/j.msard.2020.102507. Epub 2020 Sep 19.
3
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.60 岁以上多发性硬化症患者中断疾病修正治疗。
Mult Scler. 2019 Apr;25(5):699-708. doi: 10.1177/1352458518765656. Epub 2018 Mar 20.
4
Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.影响患者对多发性硬化症疾病修正疗法支付意愿的因素。
Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720. Epub 2020 Dec 24.
5
Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.米托蒽醌治疗复发缓解型和快速进展型多发性硬化症:米托蒽醌治疗后十年的临床结果
Mult Scler Relat Disord. 2020 Sep;44:102330. doi: 10.1016/j.msard.2020.102330. Epub 2020 Jun 23.
6
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
7
Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.复发缓解型多发性硬化症患者停止疾病修正治疗:对临床和 MRI 结果的影响。
Mult Scler Relat Disord. 2019 Oct;35:119-127. doi: 10.1016/j.msard.2019.07.021. Epub 2019 Jul 25.
8
Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.使用多水平模型对复发缓解型多发性硬化症的疾病进展进行建模,该模型应用于来自两个自然史队列和一个治疗队列的纵向数据。
Health Technol Assess. 2016 Oct;20(81):1-48. doi: 10.3310/hta20810.
9
Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care.探索多发性硬化症一线治疗的停药策略:患者护理的范式转变。
Mult Scler Relat Disord. 2024 Apr;84:105503. doi: 10.1016/j.msard.2024.105503. Epub 2024 Feb 15.
10
Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional study.口服疾病修正疗法——未治疗的复发缓解型多发性硬化症和临床孤立综合征患者治疗决策的变革者?——一项瑞士单中心横断面研究。
Mult Scler Relat Disord. 2022 Dec;68:104396. doi: 10.1016/j.msard.2022.104396. Epub 2022 Nov 2.

引用本文的文献

1
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.降低多发性硬化症病情修饰疗法的强度并停药
Brain. 2025 May 13;148(5):1459-1478. doi: 10.1093/brain/awae409.
2
MS treatment de-escalation: review and commentary.多发性硬化症治疗的逐步降级:综述与评论
J Neurol. 2024 Oct;271(10):6426-6438. doi: 10.1007/s00415-024-12584-x. Epub 2024 Aug 2.
3
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.多发性硬化症中疾病修正疗法的降级和停药。
Curr Neurol Neurosci Rep. 2024 Sep;24(9):341-353. doi: 10.1007/s11910-024-01355-w. Epub 2024 Jul 12.
4
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.55岁及以上个体的多发性硬化症管理:全面综述
Front Immunol. 2024 Apr 5;15:1379538. doi: 10.3389/fimmu.2024.1379538. eCollection 2024.
5
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies.停止多发性硬化症的疾病修饰治疗:一项对真实世界研究的系统评价和荟萃分析
CNS Drugs. 2023 Oct;37(10):915-927. doi: 10.1007/s40263-023-01038-z. Epub 2023 Sep 23.
6
Impact of aging on treatment considerations for multiple sclerosis patients.衰老对多发性硬化症患者治疗考量的影响。
Front Neurol. 2023 Jul 7;14:1197212. doi: 10.3389/fneur.2023.1197212. eCollection 2023.
7
Outcomes of multiple sclerosis patients admitted with COVID-19 in a large veteran cohort.COVID-19 住院的多发性硬化症患者的结局:一项大型退伍军人队列研究。
Mult Scler Relat Disord. 2022 Aug;64:103964. doi: 10.1016/j.msard.2022.103964. Epub 2022 Jun 11.
8
Therapeutic Advances in Multiple Sclerosis.多发性硬化症的治疗进展
Front Neurol. 2022 Jun 3;13:824926. doi: 10.3389/fneur.2022.824926. eCollection 2022.
9
Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?多发性硬化症的治疗挑战——醋酸格拉替雷还有继续发挥作用的空间吗?
Front Neurol. 2022 Apr 15;13:844873. doi: 10.3389/fneur.2022.844873. eCollection 2022.
10
Multiple Sclerosis Recognition by Biorthogonal Wavelet Features and Fitness-Scaled Adaptive Genetic Algorithm.基于双正交小波特征和适应度缩放自适应遗传算法的多发性硬化症识别
Front Neurosci. 2021 Sep 13;15:737785. doi: 10.3389/fnins.2021.737785. eCollection 2021.